Skip to main content
SpringerLink
Log in

Gavestinel

GV 150526, GV 150526A

  • Section 1: Neuroprotection in Stroke
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hoke JF, Dyker AG, McAllister AM, et al. Pharmacokinetics of GV150526A following multiple intravenous doses in acute stroke patients. Cerebrovasc Dis 1997 Mar; 7 Suppl. 4: 29

    Google Scholar 

  2. Lees KR, Lavelle JF, Hobbiger SF, et al. Safety and tolerability of GV150526 in acute stroke (GLYB2002). Cerebrovasc Dis 1998; 8 Suppl. 4: 20

    Google Scholar 

  3. Gaviraghi G, Pietra C, Ratti E, et al. GV150526A: a novel glycine antagonist with neuroprotective activity devoid of sideeffects associated to NMDA receptor blockade. Cerebrovasc Dis 1996; 6 Suppl. 2: 41–2

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gavestinel. Drugs R&D 1, 23–24 (1999). https://doi.org/10.2165/00126839-199901010-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901010-00008

Keywords

Search

Navigation